A rare confluence: chronic myeloid leukemia in a pediatric case of beta thalassemia

Authors

  • Preeti Agrawal Department of Pathology, American International Institute of Medical Sciences, Udaipur, Rajasthan, India
  • Lavanya Raghavan Department of Pathology, American International Institute of Medical Sciences, Udaipur, Rajasthan, India
  • Arpit Mittal Department of Hemato-Oncology, American International Institute of Medical Sciences, Udaipur, Rajasthan, India https://orcid.org/0000-0002-0296-1871

DOI:

https://doi.org/10.18203/2349-3291.ijcp20260110

Keywords:

Leucocytosis, Peripheral blood, Hepatosplenomegaly, RT(PCR), Iron overload, BCR-ABL1

Abstract

Chronic myeloid leukemia (CML) is rare in children and extremely uncommon in patients with underlying hemoglobinopathies such as beta thalassemia. This report describes a 12‑year‑old beta thalassemia patient, who presented with fever, pallor and weakness, and was found to have marked hepatosplenomegaly and leukocytosis. Peripheral blood showed leukocytosis with increased myeloid precursors and bone marrow evaluation showed hypercellular marrow with myeloid hyperplasia and basophilia, consistent with a chronic myeloproliferative neoplasm. Karyotyping revealed balanced reciprocal translocation t (9;22) and reverse‑transcriptase polymerase chain reaction (RT‑PCR) detected BCR‑ABL1 p210 fusion transcript, confirming the diagnosis of chronic phase CML in a background of beta thalassemia. The patient had elevated serum ferritin, indirect hyperbilirubinemia and mildly deranged transaminases, attributable to chronic transfusions and iron overload. After initiation of appropriate therapy, leukocyte counts normalized within one month along with disappearance of circulating immature myeloid precursors. This case highlights the importance of maintaining a high index of suspicion for CML in thalassemic patients with unexplained leukocytosis and splenomegaly, and underscores the need for integrated morphologic, cytogenetic and molecular work-up to distinguish disease progression from a second primary hematologic malignancy.

Metrics

Metrics Loading ...

References

Hijiya N, Schultz KR, Metzler M, Millot F, Suttorp M. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood. 2016;127(4):392-9. DOI: https://doi.org/10.1182/blood-2015-06-648667

Wu C, Zhang X, Ye X, Chen D, Jin J. Huang J. Co-existence of myeloproliferative neoplasias and β-thalassemia with IVS-2-654 mutation—a case report. Transl Cancer Res. 2020;9(3):2069-73. DOI: https://doi.org/10.21037/tcr.2020.01.48

Taher AT, Musallam KM, Cappellini MD. Thalassemia and HIV infection: a review. Virulence. 2016;7(Suppl 1):46–55.

Clappier E, Kaltenbach S, Schmutz A. Pediatric chronic myeloid leukemia: biology and treatment. Front Pediatr. 2023;11:1145702.

Terwilliger ME, Abdul-Hay M. Chronic myeloid leukemia: a comprehensive review. Semin Hematol. 2016;53(3):140-7.

Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European Leukemia Net 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-84. DOI: https://doi.org/10.1038/s41375-020-0776-2

Karimi M, Haghpanah S, Giti R. Malignancies in patients with β thalassemia major and β thalassemia intermedia: a multicenter study. Semin Hematol. 2009;46(4):318-25. DOI: https://doi.org/10.1002/pbc.22144

Downloads

Published

2026-01-27

How to Cite

Agrawal, P., Raghavan, L., & Mittal, A. (2026). A rare confluence: chronic myeloid leukemia in a pediatric case of beta thalassemia . International Journal of Contemporary Pediatrics, 13(2), 328–330. https://doi.org/10.18203/2349-3291.ijcp20260110

Issue

Section

Case Reports